The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3
Open accessAbstract
Lithium is one of the most widely used drugs for treating bipolar (manic-depressive) disorder. Despite its efficacy, the molecular mechanism underlying its action has not been elucidated. One recent study has proposed that lithium inhibits glycogen synthase kinase-3 and thereby affects multiple cellular functions. Because glycogen synthase kinase-3 regulates the phosphorylation of tau (microtubule-binding protein that forms paired helical filaments in neurons of the Alzheimer's disease brain), we hypothesized that lithium could affect tau phosphorylation by inhibiting glycogen synthase kinase-3. Using cultured human NT2N neurons, we demonstrate that lithium reduces the phosphorylation of tau, enhances the binding of tau to microtubules, and promotes microtubule assembly through direct and reversible inhibition of glycogen synthase kinase-3. These results provide new insights into how lithium mediates its effects in the central nervous system, and these findings could be exploited to develop a novel intervention for Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
Cross, D. A. E., Alessi, D. R., Cohen, P., Andjelkovich, M., & Hemmings, B. A. (1995) · Nature · doi:10.1038/378785a0 · Cited by 5,244
A protein factor essential for microtubule assembly
Weingarten, M. D., Lockwood, A. H., Hwo, S. Y., & Kirschner, M. W. (1975) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.72.5.1858 · Cited by 3,089
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
A molecular mechanism for the effect of lithium on development.
Klein, P. S., & Melton, D. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8455 · Cited by 2,301
Self-citationThe distribution of tau in the mammalian central nervous system.
Binder, L. I., Frankfurter, A., & Rebhun, L. I. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.4.1371 · Cited by 1,588
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418
Self-citationLithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
Stambolic, V., Ruel, L., & Woodgett, J. R. (1996) · Current Biology · doi:10.1016/s0960-9822(02)70790-2 · Cited by 1,321
Goedert, M., Spillantini, M. G., Cairns, N. J., & Crowther, R. A. (1992) · Neuron · doi:10.1016/0896-6273(92)90117-v · Cited by 1,112
Hallcher, L. M., & Sherman, W. R. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70391-3 · Cited by 1,101
Cited by
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Self-citationThe multifaceted roles of glycogen synthase kinase 3β in cellular signaling
Grimes, C. A., & Jope, R. S. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(01)00011-9 · Cited by 1,423
Tau pathology in Alzheimer disease and other tauopathies
Iqbal, K., del C. Alonso, A., Chen, S., Chohan, M. O., El-Akkad, E., Gong, C.-X., Khatoon, S., Li, B., Liu, F., Rahman, A., et al. (2005) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.09.008 · Cited by 1,037
“[95] M.”
BackgroundLucas, J. J. (2001) · The EMBO Journal · doi:10.1093/emboj/20.1.27 · Cited by 900
Coghlan, M. P., Culbert, A. A., Cross, D. A., Corcoran, S. L., Yates, J. W., Pearce, N. J., Rausch, O. L., Murphy, G. J., Carter, P. S., Roxbee Cox, L., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00025-9 · Cited by 897
GSK3 inhibitors: development and therapeutic potential
Cohen, P., & Goedert, M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1415 · Cited by 790
Molecular mechanisms of neurodegeneration in Alzheimer's disease
Crews, L., & Masliah, E. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq160 · Cited by 772
Glycogen synthase kinase-3 (GSK3): Inflammation, diseases, and therapeutics
Jope, R. S., Yuskaitis, C. J., & Beurel, E. (2007) · Neurochemical Research · doi:10.1007/s11064-006-9128-5 · Cited by 774
Leclerc, S., Garnier, M., Hoessel, R., Marko, D., Bibb, J. A., Snyder, G. L., Greengard, P., Biernat, J., Wu, Y.-Z., Mandelkow, E.-M., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m002466200 · Cited by 723
Noble, W., Planel, E., Zehr, C., Olm, V., Meyerson, J., Suleman, F., Gaynor, K., Wang, L., LaFrancois, J., Feinstein, B., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500466102 · Cited by 709
Tau protein pathology in neurodegenerative diseases
Spillantini, M. G., & Goedert, M. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(98)01337-x · Cited by 683
Mechanisms of tau-induced neurodegeneration
Iqbal, K., Liu, F., Gong, C.-X., Alonso, A. D. C., & Grundke-Iqbal, I. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0486-3 · Cited by 628
Tau phosphorylation in neuronal cell function and dysfunction
Johnson, G. V. W., & Stoothoff, W. H. (2004) · Journal of Cell Science · doi:10.1242/jcs.01558 · Cited by 624
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A.-C., Jerning, E., Markgren, P.-O., Borgegård, T., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306268200 · Cited by 552
Linking Aβ and Tau in Late-Onset Alzheimer's Disease: A Dual Pathway Hypothesis
Small, S. A., & Duff, K. (2008) · Neuron · doi:10.1016/j.neuron.2008.11.007 · Cited by 546
Chalecka-Franaszek, E., & Chuang, D.-M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8745 · Cited by 542
Beurel, E., & Jope, R. S. (2006) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.07.006 · Cited by 541
Chong, Z. Z., Li, F., & Maiese, K. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.02.004 · Cited by 536
Molecular Targets of Lithium Action
Phiel, C. J., & Klein, P. S. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.789 · Cited by 515
Self-citationSánchez, C. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00046-5 · Cited by 511
Hoshi, M., Sato, M., Matsumoto, S., Noguchi, A., Yasutake, K., Yoshida, N., & Sato, K. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1237107100 · Cited by 496
Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases
Mazanetz, M. P., & Fischer, P. M. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2111 · Cited by 459
“GSK3β has been shown to phosphorylate tau at some of the sites that are hyperphosphorylated in PHFs, both in transfected mammalian neuronal cells and in vivo”
BackgroundMeijer, L., Thunnissen, A.-M., White, A., Garnier, M., Nikolic, M., Tsai, L.-H., Walter, J., Cleverley, K., Salinas, P., Wu, Y.-Z., et al. (2000) · Chemistry & Biology · doi:10.1016/s1074-5521(00)00063-6 · Cited by 454
Inhibitory Phosphorylation of Glycogen Synthase Kinase-3 (GSK-3) in Response to Lithium
Zhang, F., Phiel, C. J., Spece, L., Gurvich, N., & Klein, P. S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212635200 · Cited by 435
Self-citationThe Role of Tau in Alzheimer's Disease and Related Disorders
Medeiros, R., Baglietto‐Vargas, D., & LaFerla, F. M. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00177.x · Cited by 432
Therapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Forlenza, O. V., Diniz, B. S., Radanovic, M., Santos, F. S., Talib, L. L., & Gattaz, W. F. (2011) · British Journal of Psychiatry · doi:10.1192/bjp.bp.110.080044 · Cited by 402
Spittaels, K., Van den Haute, C., Van Dorpe, J., Bruynseels, K., Vandezande, K., Laenen, I., Geerts, H., Mercken, M., Sciot, R., Van Lommel, A., et al. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65533-2 · Cited by 385
Glycogen Synthase Kinase-3 (GSK3) in Psychiatric Diseases and Therapeutic Interventions
Jope, R., & Roh, M.-S. (2006) · Current Drug Targets · doi:10.2174/1389450110607011421 · Cited by 382
GSK-3 and Wnt Signaling in Neurogenesis and Bipolar Disorder
Valvezan, A. J., & Klein, P. S. (2012) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2012.00001 · Cited by 382
Self-citationHernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Interactions between β-amyloid and central cholinergic neurons: implications for Alzheimer’s disease
Kar, S., Slowikowski, S. P. M., Westaway, D., & Mount, H. T. J. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0442 · Cited by 364
GSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
Manji, H. K., Moore, G. J., & Chen, G. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00979-3 · Cited by 352
The Roles of Cyclin-dependent Kinase 5 and Glycogen Synthase Kinase 3 in Tau Hyperphosphorylation
Plattner, F., Angelo, M., & Giese, K. P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603469200 · Cited by 340
Neuroplasticity and cellular resilience in mood disorders
Manji, H. K., Moore, G. J., Rajkowska, G., & Chen, G. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000811 · Cited by 340
Martinez, A., Castro, A., Dorronsoro, I., & Alonso, M. (2002) · Medicinal Research Reviews · doi:10.1002/med.10011 · Cited by 333
De Ferrari, G. V., Chacón, M. A., Barría, M. I., Garrido, J. L., Godoy, J. A., Olivares, G., Reyes, A. E., Alvarez, A., Bronfman, M., & Inestrosa, N. C. (2003) · Molecular Psychiatry · doi:10.1038/sj.mp.4001208 · Cited by 332
Zheng, W.-H., Bastianetto, S., Mennicken, F., Ma, W., & Kar, S. (2002) · Neuroscience · doi:10.1016/s0306-4522(02)00404-9 · Cited by 321
Spittaels, K., Van den Haute, C., Van Dorpe, J., Geerts, H., Mercken, M., Bruynseels, K., Lasrado, R., Vandezande, K., Laenen, I., Boon, T., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006219200 · Cited by 316
Lithium at 50: have the neuroprotective effects of this unique cation been overlooked?
Manji, H. K., Moore, G. J., & Chen, G. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00165-1 · Cited by 313
Lucas, F. R., Goold, R. G., Gordon-Weeks, P. R., & Salinas, P. C. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.10.1351 · Cited by 301
Su, Y., Ryder, J., Li, B., Wu, X., Fox, N., Solenberg, P., Brune, K., Paul, S., Zhou, Y., Liu, F., et al. (2004) · Biochemistry · doi:10.1021/bi035627j · Cited by 296
Wnt signaling function in Alzheimer’s disease
De Ferrari and, G. V., & Inestrosa, N. C. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00021-7 · Cited by 289
Baki, L., Shioi, J., Wen, P., Shao, Z., Schwarzman, A., Gama‐Sosa, M., Neve, R., & Robakis, N. K. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600251 · Cited by 289
Cho, J., & Johnson, G. V. W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02155.x · Cited by 282
Goold, R. G., Owen, R., & Gordon-Weeks, P. R. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.19.3373 · Cited by 281
Disease-modifying therapies for Alzheimer disease: Challenges to early intervention
Cummings, J. L., Doody, R., & Clark, C. (2007) · Neurology · doi:10.1212/01.wnl.0000295996.54210.69 · Cited by 279
Judging a Protein by More Than Its Name: GSK-3
Woodgett, J. R. (2001) · Science's STKE · doi:10.1126/stke.2001.100.re12 · Cited by 279
A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation
Paquet, D., Bhat, R., Sydow, A., Mandelkow, E.-M., Berg, S., Hellberg, S., Fälting, J., Distel, M., Köster, R. W., Schmid, B., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37537 · Cited by 278
α‐Synuclein contributes to GSK‐3β‐catalyzed Tau phosphorylation in Parkinson's disease models
Duka, T., Duka, V., Joyce, J. N., & Sidhu, A. (2009) · The FASEB Journal · doi:10.1096/fj.08-120410 · Cited by 275
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Minati, L., Edginton, T., Grazia Bruzzone, M., & Giaccone, G. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 268
Filamentous nerve cell inclusions in neurodegenerative diseases
Goedert, M., Spillantini, M. G., & Davies, S. W. (1998) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(98)80090-1 · Cited by 262
Engel, T., Hernández, F., Avila, J., & Lucas, J. J. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0604-06.2006 · Cited by 260
Song, L., De Sarno, P., & Jope, R. S. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206047200 · Cited by 256
Engel, T., Goñi‐Oliver, P., Lucas, J. J., Avila, J., & Hernández, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04139.x · Cited by 223
GSK‐3 in Neurodegenerative Diseases
Lei, P., Ayton, S., Bush, A. I., & Adlard, P. A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/189246 · Cited by 177
“However, in accordance with cell culture studies [53, 127–129] GSK-3 activity remained the same in a long-term (5 months) lithium trial [74], possibly suggesting that the protection offered by lithium is GSK-3 independent.”
BackgroundResultCdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats
Wen, Y., Yang, S.-H., Liu, R., Perez, E. J., Brun-Zinkernagel, A. M., Koulen, P., & Simpkins, J. W. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2006.10.011 · Cited by 162
Chang, K.-A., Kim, H.-S., Ha, T.-Y., Ha, J.-W., Shin, K. Y., Jeong, Y. H., Lee, J.-P., Park, C.-H., Kim, S., Baik, T.-K., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02393-05 · Cited by 161
Drug development for Alzheimer's disease: where are we now and where are we headed?
Sabbagh, M. N. (2009) · The American journal of geriatric pharmacotherapy · doi:10.1016/j.amjopharm.2009.06.003 · Cited by 147
Lithium: the pharmacodynamic actions of the amazing ion
Brown, K. M., & Tracy, D. K. (2013) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125312471963 · Cited by 140
Hartigan, J. A., & Johnson, G. V. W. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.30.21395 · Cited by 141
Tau and Axonopathy in Neurodegenerative Disorders
Higuchi, M., Lee, V. M.-Y., & Trojanowski, J. Q. (2002) · NeuroMolecular Medicine · doi:10.1385/nmm:2:2:131 · Cited by 134
Self-citationβ-amyloid redirects norepinephrine signaling to activate the pathogenic GSK3β/tau cascade
Zhang, F., Gannon, M., Chen, Y., Yan, S., Zhang, S., Feng, W., Tao, J., Sha, B., Liu, Z., Saito, T., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay6931 · Cited by 133
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Henriksen, E. J., Kinnick, T. R., Teachey, M. K., O'Keefe, M. P., Ring, D., Johnson, K. W., & Harrison, S. D. (2003) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00346.2002 · Cited by 108
Leroy, K., Ando, K., Héraud, C., Yilmaz, Z., Authelet, M., Boeynaems, J.-M., Buée, L., De Decker, R., & Brion, J.-P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1276 · Cited by 103
“Lithium is a known inhibitor of GSK-3 β [11,12] and has been found to decrease tau phosphorylation in cultured neurons [13–15]and in rat brain [14].”
Fuentealba, R. A., Liu, Q., Kanekiyo, T., Zhang, J., & Bu, G. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.021030 · Cited by 97
The role of tau in Alzheimer's disease
Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00002-0 · Cited by 85
Self-citationHsu, P.-H., Lin, Y.-T., Chung, Y.-H., Lin, K.-J., Yang, L.-Y., Yen, T.-C., & Liu, H.-L. (2018) · Scientific Reports · doi:10.1038/s41598-018-31071-8 · Cited by 70
Li, Z., Yin, B., Zhang, S., Lan, Z., & Zhang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115817 · Cited by 54
Choi, C. H., Schoenfeld, B. P., Bell, A. J., Hinchey, J., Rosenfelt, C., Gertner, M. J., Campbell, S. R., Emerson, D., Hinchey, P., Kollaros, M., et al. (2016) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2016.00136 · Cited by 46
Astrocytic uptake of neuronal corpses promotes cell‐to‐cell spreading of tau pathology
Mothes, T., Portal, B., Konstantinidis, E., Eltom, K., Libard, S., Streubel-Gallasch, L., Ingelsson, M., Rostami, J., Lindskog, M., & Erlandsson, A. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01589-8 · Cited by 43
HERNANDEZ, F. (2003) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.04.002 · Cited by 41
Progress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0012-x · Cited by 32
Unraveling the Molecular Mechanisms Behind the Metabolic Basis of Sporadic Alzheimer's Disease
Erol, A. (2008) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1047 · Cited by 30
Chen, K., Gupta, R., Martín‐Ávila, A., Cui, M., Xie, Z., & Yang, G. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.13464 · Cited by 19
(2014) · PubMed
Metadata
- Authors
- Hong, M., Chen, D. C. R., Klein, P. S., & Lee, V. M.-Y.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 1997-10
- Volume
- 272
- Issue
- 40
- Pages
- 25326-25332
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2073292164
- Cited by
- 469
- References
- 60
- FWCI
- 10.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.